GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Total Stockholders Equity

Paion Ag (Paion Ag) Total Stockholders Equity : $-3.32 Mil (As of Jun. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag Total Stockholders Equity?

Paion Ag's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-3.32 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Paion Ag's Book Value per Share for the quarter that ended in Jun. 2023 was $-0.47. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Paion Ag's Debt-to-Equity for the quarter that ended in Jun. 2023 was -6.93.

Paion Ag Total Stockholders Equity Historical Data

The historical data trend for Paion Ag's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paion Ag Total Stockholders Equity Chart

Paion Ag Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.69 16.37 25.90 7.91 7.01

Paion Ag Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.95 7.91 17.78 7.01 -3.32

Paion Ag  (OTCPK:PAIOF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Paion Ag's Book Value per Share for the quarter that ended in Jun. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-3.322-0)/7.1337
=-0.47

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Paion Ag's Debt-to-Equity for the quarter that ended in Jun. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.004 + 20.018) / -3.322
=-6.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paion Ag Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Paion Ag's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Paion Ag (Paion Ag) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Total Stockholders Equity
Comparable Companies
FRA:SPB HAM:GWK3 STU:DWB FRA:BBI HAM:TLG ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX HKSE:03692 TSE:4507 NSE:DIVISLAB BOM:500124 BOM:532321
Traded in Other Exchanges
PA8:Germany
Address
Heussstrasse 25, Aachen, DEU, 52078
Website
https://www.paion.com
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.